EPISODE · Sep 21, 2017 · 8 MIN
Can We Simplify the Treatment of Myelofibrosis?
from Journal of Clinical Oncology (JCO) Podcast · host Vikas Gupta
In this randomized trial, momelotinib was non-inferior to ruxolitinib for spleen response but was less effective in controlling symptoms. Related Article: SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor–Naïve Patients With Myelofibrosis
NOW PLAYING
Can We Simplify the Treatment of Myelofibrosis?
No transcript for this episode yet
Similar Episodes
Mar 26, 2026 ·1m
Mar 19, 2026 ·34m
Feb 18, 2026 ·11m
Feb 11, 2026 ·45m